Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
QL2107 + pemetrexed + carboplatin
- Development stage
- Phase 3
- Lead developer
- Qilu Pharmaceutical
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
QL2107 + pemetrexed + carboplatin is an investigational combination drug regimen consisting of QL2107 (a novel agent with limited public information available), pemetrexed (a folate antimetabolite chemotherapeutic also known as Alimta), and carboplatin (a platinum-based chemotherapeutic). Pemetrexed inhibits several enzymes involved in folate metabolism and DNA synthesis, while carboplatin forms DNA crosslinks which prevent cell replication. This combination is developed for the treatment of advanced non-small cell lung cancer (NSCLC) and potentially other malignancies. Mechanism of action for QL2107 is not defined in available public literature as of September 2025.
- Other names
- carboplatin
02
Targets
DNADHFR (Dihydrofolate reductase)GART (GAR transformylase)TS (Thymidylate synthase)
Beyond the preview
Go deeper on QL2107 + pemetrexed + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on QL2107 + pemetrexed + carboplatin.